


Product Name : Salirasib
Cat. No. : PC-28064
CAS No. : 162520-00-5
Molecular Formula : C₂₂H₃₀O₂S
Molecular Weight : 358.54
Target : Ras
Solubility : 10 mM in DMSO



Biological Activity

Salirasib (S-Farnesylthiosalicylic acid, FTS) is an oral **RAS** inhibitor, shows potent competitive inhibitor of prenylated protein methyltransferase (**PPMTase**) with K_i of 2.6 μM, inhibits the active forms of Ras proteins.

Salirasib selectively inhibits growth of human Ha-ras-transformed Rat1 cells in vitro with EC₅₀ of 7.5 μM.

Salirasib interferes with the activation of Raf-1 and MAPK and inhibits DNA synthesis in Ras-transformed EJ cells.

Salirasib also inhibits MAPK activity and DNA synthesis stimulated by serum, EGF or thrombin in serum-starved untransformed Rat-1 cells.

Salirasib affects Ras membrane association but not Ras farnesylation.

Salirasib mimics c-terminal farnesyl cysteine, common to all RAS isoforms, and competes with farnesylated RAS for putative-binding sites on the plasma membrane, leading to degradation of active cytoplasmic RAS.

References

Marciano D, et al. *J Med Chem.* 1995 Apr 14;38(8):1267-72.

Marom M, et al. *J Biol Chem.* 1995 Sep 22;270(38):22263-70.

Gana-Weisz M, et al. *Biochem Biophys Res Commun.* 1997 Oct 29;239(3):900-4.

Furuse J, et al. *Cancer Chemother Pharmacol.* 2018 Sep;82(3):511-519.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com